State of the Art 2025 RD Report: Ireland

1:1
This 2025 country report outlines the policy, research, care and support landscape for rare diseases in Ireland.

This report gives an overview of rare disease activities in Ireland in 2025, including the national action plan, research and funding, registration and biobanking, organisation of care, newborn screening, diagnostics, patient organisations, information resources, training and orphan medicinal products.

You might also be interested in

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
The European Rare Diseases Research Alliance (ERDERA), together with the European Reference Networks (ERNs), provides the missing operational layer required to implement the European Biotech Act across the full innovation pathway —from discovery to patient access.
ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.